Innate Pharma (IPHA) — Cash Flow Quality Index
Innate Pharma (IPHA) has a Cash Flow Quality Index of -6.67x as of June 2023. Operating cash flow of $-11.46 Million is below net income of $1.72 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore IPHA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Innate Pharma Cash Flow Quality Index (2016–2018)
Historical Cash Flow Quality Index for Innate Pharma across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check IPHA tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Innate Pharma (2016–2018)
Year-by-year earnings quality comparison for Innate Pharma. For live market cap and the full company financial profile, see market cap of Innate Pharma.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2018 | -10.67x | $-32.53 Million | $3.05 Million | ▼ -266.0% |
| 2016 | -2.92x | $-36.85 Million | $12.64 Million | — |